Logo_UCBC.jpg
University Cancer & Blood Center’s Dr. Ashley Ray receives oncoplastic breast surgery certification
February 06, 2025 11:48 ET | University, Cancer and Blood Center
University Cancer & Blood Center (UCBC), based in Athens, Georgia, announces that Dr. Ashley Ray now has her certification in oncoplastic breast surgery.
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Announces Additional Synthesized Compounds in its AI-Driven Cancer Drug Discovery Program
February 06, 2025 08:30 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on DNA-damage response...
ALLARITY Full Color RGB 2023JUN07.png
Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer
February 06, 2025 08:00 ET | Allarity Therapeutics, Inc.
Boston (February 6, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a...
Immuneering-color-logo-CMYK_Resized.jpg
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
February 06, 2025 07:00 ET | Immuneering Corporation
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
sns insider pvt ltd.png
Nuclear Medicine Market Size to Accumulate Around USD 38.8 Billion by 2032, Growing at a 15% CAGR - SNS Insider
February 05, 2025 09:30 ET | SNS Insider pvt ltd
Pune, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Nuclear Medicine Market Size & Growth Analysis: According to SNS Insider, The Global Nuclear Medicine Market size was valued at USD 11.1 billion in 2023...
AIMLogo.jpg
Erasmus Medical Center Safety Committee Grants Approval to Proceed with Phase 2 Study of Ampligen® and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
February 05, 2025 08:00 ET | AIM ImmunoTech Inc.
Safety Committee approval based on positive Phase 1 safety data demonstrating the combination therapy to be generally well-tolerated with no severe treatment-related adverse events or dose-limiting...
medicenna.jpg
Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025
February 05, 2025 07:00 ET | Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused...
Immuneering-color-logo-CMYK_Resized.jpg
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 03, 2025 16:05 ET | Immuneering Corporation
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Straits Logo 1-01 (1).png
Cancer Diagnostics Market Size is Expected to Reach USD 178.26 Billion by 2033, Growing at a CAGR of 5.91%: Straits Research
February 03, 2025 08:25 ET | Straits Research Private Limited - Garner Insights
New York, United States, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Cancer diagnostics is the process of identifying biomarkers, proteins, and other indicators that assist in identifying a cancerous tumor....
arvinas_logoART_lg.jpg
Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
February 03, 2025 07:00 ET | Arvinas Inc.
NEW HAVEN, Conn., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...